Monday, May 30, 2016 9:28:09 PM
"S-3 Registrations expire after 3 years. The recent shelf registration is merely replacing the original S-3 Registration Statement (effective February 4, 2013). The original S-3 was for $150mm with up to $30mm via Cantor in a Controlled Equity Offering. Over the 3 years, TROV issued 2 offerings from the original S-3 in Feb 2015 and July 2015. As far as I know, no sales to Cantor were made during that time under the Controlled Equity Offering
The new S-3 is for $250mm with up to the same $30mm via Cantor in a Controlled Equity Offering. This does not mean that there is anything imminent on the horizon. At the projected burn rate, TROV will definitely need cash sometime by Q2 2017. But just like in July 2015, I'm sure TROV will be opportunistic if the stock jumps unexpectedly to raise cash. Cash is king in the LB space."
This post is from solo_nyc and IMO summarizes current events very well.
Recent CRDF News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:55 PM
- Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:00:13 PM
- Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/17/2024 10:10:38 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 08:06:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:03:35 PM
- Cardiff Oncology to Present at the Jefferies Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 08:05:00 PM
- Cardiff Oncology to Present at Upcoming Investor Conferences in May • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study • GlobeNewswire Inc. • 04/08/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:40 PM
- Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:07:00 PM
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC • GlobeNewswire Inc. • 02/29/2024 09:06:00 PM
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:00:21 PM
- Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:01:34 PM
- Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research • PR Newswire (US) • 01/17/2024 03:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM